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Abstract
Diabetes mellitus is a group of metabolic diseases characterized by  
hyperglycaemia resulting from defects in insulin secretion, insulin action or both. 
Diabetes affects many systems and produces complications in the human body, in 
those complications one is diabetic central neuropathy. The pathological mecha-
nisms involved in the central neuropathy include chronic hyperglycaemia, hypogly-
caemic episodes, angiopathy and blood–brain barrier dysfunction. Diabetic central 
neuropathy is detected by using of brainstem auditory evoked response (BAER), 
Visual evoked potential (VEP), somatosensory evoked potential (SEP). These 
abnormalities are present at different levels and may appear before appearance of 
overt complications. The central nervous system abnormalities are more frequent 
in patients with peripheral neuropathy but evoked potentials can be abnormal even 
in patients without neuropathy. The BAER is a physiological recording technique to 
study the auditory pathway and does not require subject’s attention and generates 
waves during the first 10 ms after the sound stimulus. Each BAER wave is generated 
by the activation of a sub-cortical component of the auditory pathway with 90% 
sensitivity and 70–90% of specificity.
Keywords: Brainstem auditory evoked response, central neuropathy, hearing 
impairment, inter peak latency, type 2 diabetes mellitus
1. Introduction
Diabetes mellitus causes both peripheral and central neuropathy, but the 
peripheral diabetic neuropathy manifestations are more frequently discussed in the 
literature than the central diabetic neuropathy [1]. The central nervous system has 
wide, divergent afferent and efferent connections to integrate and transduced the 
whole body functions like homeostatic adjustments of food intake, energy expendi-
ture, and nutrient metabolism [2].
The auditory nervous system is a complex and intricate structure and performs 
many tasks in daily life; it analyzes, synthesizes, commands sensory information 
and carries out decisions; it is measured by using a powerful tool, auditory brain-
stem evoked response, is capable of both detection and diagnosis of brainstem 
lesions [3]. The auditory nervous system consists of ascending and descending 
pathways. Ascending pathway has the classical and non-classical pathways. The 
classical auditory pathways are known as the tonotopic system because they have 
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distinct frequency tuning and the neurons are organized anatomically according to 
the frequency to which they are tuned. Non-classical pathway used the dorsal nuclei 
of the thalamus and that project to secondary auditory cortex rather than primary 
auditory cortex. Again the non-classical pathway divided into two separate systems, 
the diffuse and the polysensory pathways. Descending pathway has the corticofugal 
and the olivocochlear pathways. Descending auditory pathways are organized 
mostly parallel to the ascending pathways extending from the cerebral cortex to the 
cochlear hair cells [4].
Evoked potentials are helpful very much to study the diabetic change in central 
neural structures [5]. Diabetic central neuropathy is detected by using of brainstem 
auditory evoked response (BAER), Visual evoked potential (VEP), somatosensory 
evoked potential (SEP) [5, 6]. These abnormalities are present at different levels 
and may appear before appearance of overt complications. The central nervous 
system abnormalities are more frequent in patients with peripheral neuropathy 
but evoked potentials can be abnormal even in patients without neuropathy. The 
pathological mechanisms involved in the central neuropathy include chronic 
hyperglycaemia, hypoglycaemic episodes, angiopathy and blood–brain barrier 
dysfunction [7].
The BAER is a physiological recording technique to study the auditory pathway 
and does not require subject’s attention and generates waves during the first 10 ms 
after the sound stimulus. Each ABR wave is generated by the activation of a sub-
cortical component of the auditory pathway [8] with 90% sensitivity and 70–90% 
of specificity [9]. Despite its fall from favor as the initial test of choice in suspected 
brainstem or VIIIth cranial nerve disease, important clinical roles for BAER still 
exist. It should be remembered that BAER assess functions of auditory pathways 
whereas neuroimaging studies examine structure [10].
2. Materials and methods
2.1 Research design
The research design is cross sectional study. The control group included normal 
subjects, T2DM patients without hearing impairment of either sex, who is not suf-
fering from hearing problems. The sampling technique was sequential sampling.
2.2 Participants
The present study was carried out at Mediciti Institute of Medical Sciences 
(MIMS), Hyderabad, India during the period of 2015 to 2016. This study was 
approved by institutional ethical committee (FWA00002084; dated 16/03/2015). 
In this study three groups i.e. WoHI (n = 50), WHI (n = 50) and normal subjects 
(n = 10) of either sex with an age group of 35–55 were included. The participants 
were enrolled in the study after acquiring the informed consent.
2.3 Inclusion and exclusion criteria
Type 2 diabetic patients with (WHI) and without (WoHI) hearing impairment, 
both the gender was included with age limit between 35 and 55 years; minimum 
duration of diabetes after the diagnosis was 5 years and also ten normal subjects 
were included as controls.
Participants who had a history of immune/metabolic diseases like hyperbiliru-
binaemia/kernicterus, polyarteritis nodosa, type 1 diabetes, paraproteinaemias, 
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anoxia/hypoxia, sarcoidosis, rheumatoid arthritis, uraemia, Guillain-Barré 
Syndrome, chronic infections like Leprosy, AIDS, Borreliosis, Ramsey Hunt 
syndrome, using heavy metals like lead, cobalt, mercury; drugs like carboplatin, 
methyldopa and reserpine; neoplasma/intracranial cystic lesions, chronic middle 
ear diseases, cranial trauma, ear surgeries, recent surgeries, congenital problems, 
noise exposure, smoking, alcoholism, hypertension, stroke and hepatic encepha-
lopathy were excluded from the study.
2.4 Sample size calculation
The sample size was calculated in the OpenEpi statistical software. In the pilot 
study, screening for hearing was carried out for both the ears in fifteen individuals 
by using pure tone audiometry. In the right ear, 9 out of 15 had a hearing impair-
ment, and 5 out of 9 (55.5%) participants with hearing impairment had diabetes. 
Out of the 6 (16.7%) individuals without hearing impairment only one had diabe-
tes. Using these values sample size was calculated as 27 each for controls and test. In 
the left ear, 10 out of 15 had a hearing impairment, and 5 out of 10 (50%) subjects 
with hearing impairment had diabetes. Out of the 5 (20%) individuals without 
hearing impairment only one had diabetes. Using these values sample size was 
calculated as 45 each for controls and test. So in the present study 50 was considered 
as sample size for each group.
2.5 Calculation of BMI
Height and weight were measured on the subjects in standing position. The 
weighing scales and the measuring tapes were calibrated periodically. BMI was cal-
culated from the formula, BMI = weight (kg) /height2 (mts). BMI normal values are 
below 18.5 (underweight), 18.5–24.9 (normal), 25.0–29.9 (pre obesity), 30.0–34.9 
(obesity class I), 35.0–39.9 (Obesity class II) and Above 40 (Obesity class III).
2.6 Measurement of HbA1c
In diabetes, long-term maintenance of blood glucose is important to prevent 
complications. HbA1cis an indicator of the average glucose concentration in the 
blood over a period of four months. The HbA1c was measured by using anticaogu-
lated venous blood with latex agglutination inhibition assay (the absence of agglu-
tination is diagnostic of antigen provides a high sensitive assay for small quantities 
of antigen) with “Rx imola automated analyser (open system)”. Protease enzyme in 
the hemoglobin denaturant reagent lyses red blood cells and causes hydrolysis of the 
hemoglobin. The concentration of HbA1c and the total hemoglobin concentrations 
are measured and HbA1c was calculated as a % of the total hemoglobin concentra-
tion. A normal range of HbA1c was 4–6.5% (normal), 6.5–7.5% (target range for 
those with diabetes), 8–9.5% (high) and greater than 9.5% (very high).
2.7 Measurement of pure tone average (PTA)
The levels of hearing impairment are assessed with the help of Pure Tone 
Audiometry and obtain pure tone thresholds during air and bone conduction test-
ing. They are recorded graphically on the “audiogram”. The audiogram is graph of a 
patient’s hearing thresholds across the frequency octaves from 250 Hz to 8000 Hz.
The audiogram provides both qualitative and quantitative information about the 
patient’s hearing loss. Quantitative information tells about degree of loss based on 
the pure tone average (PTA) of AC thresholds and calculated as decibels (dB). PTA 
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normal ranges for hearing impairment are −10 to 15 (normal), 16 to 25 (slight), 26 
to 40 (mild), 41 to 55 (moderate), 56 to 70 (moderately severe), 71 to 90 (severe), 
91 and above (profound). Qualitative information tells about type of hearing 
impairment and helps in topological diagnosis.
2.8 Recording of brainstem auditory evoked response
The BAER is a sequential electrical potential generated in the brainstem and 
auditory pathway in response to stimulus and is recorded as wave forms from wave 
I to wave VII and these peaks are generated from different sites of the brainstem 
auditory pathway. It helps in analyzing presence or absence of hearing loss at the 
level of central auditory pathway. In the present BAER is recorded by using instru-
ment “Biologic Navigator Pro system AEP Software version 6.3” Natus Medical 
Incorporated USA, 2013.
2.8.1 Stimulus types
An ideal stimulus for eliciting BEAR is a click, which is a brief rectangular pulse 
of 50–200 μs duration with an instantaneous onset. The rapid onset of click pro-
vides good neural synchrony, thereby eliciting a clearly defined BAER.
2.8.2 Electrode application
Skin must be thoroughly cleaned to remove excess oil, dead skin and dirt to 
obtain a good contact between skin and electrode. Electrodes are filled with a 
conducting cream and taped into place. Once the electrodes have been applied, 
adequacy of contact with skin is assessed by measuring electrical impedance 
between each electrode pair. For high quality recording, inter electrode impedance 
≤5 kΩ is acceptable.
2.8.3 Processing of electrical activity
Electrical activity picked up by the recording electrodes within the specified 
time window must be processed through several stages to visualize the BAER 
waveform. This is because the BAER peaks are of extremely small voltage (>1 μV) 
and are buried in a background of interference (termed ‘noise’), which includes 
ongoing electroencephalogram (EEG) activity, muscle potentials caused by move-
ment or tension, and 50 Hz power-line radiation. The stages of processing include 
amplification, filtering, and signal averaging.
2.8.4 Amplification and filtering
The small size of the BAER peaks requires amplification to increase the magni-
tude of the electrical activity picked up by the electrodes. An amplifier gain of 105 is 
typically used. The problem of interference obscuring the BAER can be diminished 
partially by filtering the electrical activity coming from the electrodes. Band pass 
filters are used to accept energy only within the particular frequency band of inter-
est and reject energy in other frequency ranges. For BAER recording, a filter setting 
of 30–3000 Hz is recommended to enhance the BAER when testing infants.
Filtering can only eliminate a portion of the interfering noise because of overlap 
between the frequency content of the BAER and the frequency of the interference. 
Therefore, another technique, called signal averaging, must be used to further 
reduce unwanted interference.
5
Brainstem Auditory Evoked Potentials in Type 2 Diabetes Mellitus
DOI: http://dx.doi.org/10.5772/intechopen.97469
2.8.5 Signal averaging
The BAER is very small, and even with filtering, it is buried with a background 
of noise. Signal averaging helps to reduce this noise so that the signal, in this case 
the BAER, can be detected. Signal averaging is possible because the BAER is time-
locked to stimulus onset, whereas the noise interference occurs randomly. That is, 
the signal occurs at the same points in time following onset of the eliciting stimulus, 
but the noise has no regular pattern. In signal averaging, a large number of stimuli 
are presented, and the responses to each of the individual stimulus presentations 
(termed ‘sweeps’) are averaged together to obtain a final averaged waveform. By 
averaging, the random noise tends to cancel out, whereas the evoked potential is 
retained because it is basically the same in each sweep. The greater the number of 
stimulus presentations used, the greater the improvement in signal to noise ratio, 
and the more clearly the BAER can be visualized in the final averaged waveform.
2.8.6 Procedure
The patient is made to lie down in a relaxed position with eyes closed so that no 
auro-palpaberal reflex could be picked up. The portion behind the ear i.e., mastoid on 
both sides and the forehead are rubbed gently with a conductive gel such that it allows 
to maintain adequate impedance for the testing. Measures are taken that there no 
particulars in the testing area that could cause electrical artifacts. Care should also be 
taken that the wires embedded to the instrument are un-tangled. Considering the test 
particulars, click stimulus with an alternating polarity are used at intensity levels 80, 
70, 60, 50, 40, 30 dB NHL. The filter setting that is set ranges from 150 Hz–1500 Hz, 
with an epoch time of 10.26 ms and stimulus rate of 11.1/sec and 1024 sweeps of 
stimulus. The waveform thus displayed post averaging process on the screen is 
analyzed and the peaks I, III and V are noted. The results thus obtained are analyzed 
for the final diagnosis considering the absolute latencies of peaks I, III and V and 
inter peak latencies of I-III, III-V and III-V respectively. Waves I-VII are originated 
from cochlear nerve, cochlear nucleus, superior olivary complex, lateral lemniscus, 
inferior colliculus, medial geniculate body and auditory cortex respectively.
2.8.7 Interpretation
IPL I-III is the conduction from the eighth nerve across the subarachnoid space, 
into the core of the lower pons; normal is 2 milli secs and abnormal is ˃2.4 milli 
secs. IPL III-V is the conduction from the lower to the upper pons and possibly into 
the midbrain; normal is 2 milli secs and abnormal is ˃2.4 milli secs. IPL I-V is the 
conduction from the proximal eighth nerve through pons and into the midbrain; 
normal 4 milli secs and abnormal is ˃4.4 milli secs.
3. Statistical analysis
All the data were expressed as mean ± SE. The mean were analyzed by one way 
ANOVA (Student–Newman–Keuls method). Pearson correlation test was done to 
see the relationship between right and left ear inter peak latencies of wave I-III, III-V 
and I-V values in normal subjects, WoHI and WHI groups. Pearson correlation test 
was done to see the relationship between inter peak latencies I-III, III-V and I-V with 
age, BMI and HbA1c values in normal subjects, WoHI and WHI groups for both the 
ears. For all the statistics and graph plotting, SigmaPlot 13.0 (Systat software, USA) 
was used. P < 0.05 was considered as significant.
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Figure 1. 
The IPL I-III in normal subjects, type 2 diabetes without (WoHI) and with (WHI) hearing impairment. 
Mean + SE (n ± 50 each in WoHI and WHI groups, n ± 10 in normal subjects). The ‘F’ and P values are 
comparing normal subjects, WoHI and WHI of right and left ear. a – Significantly different from normal 
subjects; b – Significantly different from WoHI group.
4. Results
The comparison of IPLs I-III, III-V and I-V of both the ears in normal subjects, 
WoHI and WHI groups were done by one way analysis of variance and it was 
represented in Table 1 with their mean and standard error of mean. The compari-
son of IPL I-III of BAER of both the ears in normal subjects, WoHI and WHI groups 
were given in Figure 1. The IPL I-III of both the ears in WHI group was statistically 
different from normal subjects and WoHI groups (P < 0.0001), this showed that 
IPL I-III increased in both ears of WHI group. The correlation of IPL I-III values of 
both the ears in WoHI and WHI groups were given in Figure 2. Negative correlation 
is seen in WoHI group for both the ears (P = 0.730), whereas in WHI group it is 
statistically significant (P = 0.050).
The comparison of IPL III-V of BAER of both the ears in normal subjects, WoHI 
and WHI groups were given in Figure 3. The right ear IPL III-V of WHI group 







IPL I-III (ms) Right 1.688 ± 0.059 1.895 ± 0.048 2.241 ± 0.039 Given in 
Figure 1
Left 1.695 ± 0.056 2.027 ± 0.317 2.187 ± 0.048
IPL III-V (ms) Right 1.596 ± 0.044 1.896 ± 0.048 1.930 ± 0.053
Left 1.521 ± 0.051 1.818 ± 0.053 1.662 ± 0.038
IPL I-V (ms) Right 3.081 ± 0.201 4.083 ± 0.050 4.170 ± 0.058
Left 2.919 ± 0.174 3.845 ± 0.052 3.715 ± 0.043
Table 1. 
One way analysis of variance of IPLs in normal subjects, T2DM WoHI and WHI groups.
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Figure 2. 
Correlation of IPL I-III (ms) in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
n = 50 each. The ‘r’ and P values are correlating WoHI and WHI right and left ear.
Figure 3. 
The IPL III-V in normal subjects, type 2 diabetes without (WoHI) and with (WHI) hearing impairment. 
Mean + SE (n ± 50 each in WoHI and WHI groups, n ± 10 in normal subjects). The ‘F’ and P values are 
comparing normal subjects, WoHI and WHI of right and left ear. a – Significantly different from normal 
subjects; b – Significantly different from WoHI group.
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(P = 0.022) were statistically different from normal subjects, WoHI group. The left 
ear IPL III-V of WoHI group is significantly different from normal subjects whereas 
WHI group is significantly different from WoHI group. This showed that IPL III-V 
increased in both ears of WHI group. The correlation of IPL III-V values of both 
the ears in WoHI and WHI groups were given in Figure 4. No correlation is seen in 
WoHI and WHI groups for both the ears. Negative correlation is seen WoHI group 
for both the ears (P = 0.100).
The comparison of IPL I-V of BAER of both the ears in normal subjects, WoHI 
and WHI groups were given in Figure 5. In WoHI and WHI groups (P < 0.0001), 
both the ears showed significant difference from the normal subjects. The cor-
relation of IPL I-V values of both the ears in WoHI and WHI groups were given in 
Figure 6. No correlation was seen in WoHI and WHI groups for both the ears.
The correlation of IPL values and age, BMI, HbA1c values for both the ears in 
normal subjects were given in Table 2. The age, BMI, HbA1c values are not correlated 
with IPL values in normal subjects. The correlation of IPL values and age, BMI, HbA1c 
values for both the ears in all subjects were given in Table 3. The BMI correlated with 
the IPL I-V (P = 0.003) of both the ears and HbA1c values correlated with IPL I-III 
(P = 0.003), I-V (P < 0.001) values of both ears in all subjects. This showed that with 
increase in BMI and HbA1c values, the IPL values are increased in diabetic subjects.
The correlation of IPL I-III, III-V and I-V values and age for both the ears in WoHI 
and WHI groups were given in Figures 7–9. In both the groups IPL I-III, III-V and I-V 
values were not statistically correlated with age. In the IPL I-III, left ear (P = 0.262) 
of WoHI and right ear (P = 0.735) of WHI groups shows negative correlation with 
age. In the IPL III-V, right ear (P = 0.460) of WoHI group shows negative correlation 
with age. In the IPL I-V, right (P = 0.757) and left (P = 0.433) ears of WoHI group and 
left (P = 0.826) ear of WHI group shows negative correlation with age.
Figure 4. 
Correlation of IPL III-V (ms) in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
n = 50 each. The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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The correlation of IPL I-III, III-V and I-V values and BMI for both the ears 
in WoHI and WHI groups were given in Figures 10–12. In both the groups IPL 
I-III, III-V and I-V values were not statistically correlated with BMI. In IPL I-III, 
Figure 5. 
The IPL I-V in normal subjects, type 2 diabetes without (WoHI) and with (WHI) hearing impairment. 
Mean + SE (n ± 50 each in WoHI and WHI groups, n ± 10 in normal subjects). The ‘F’ and P values are 
comparing normal subjects, WoHI and WHI of right and left ear. a – Significantly different from normal 
subjects; b – Significantly different from WoHI group.
Figure 6. 
Correlation of IPL I-V (ms) in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. n = 50 
each. The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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S.No Independent variable Dependent variable Ear r-value p-value
1. Age (years) IPL I-III Rt 0.081 0.397
Lt −0.002 0.978
IPL III-V Rt 0.057 0.550
Lt 0.032 0.737
IPL I-V Rt 0.062 0.516
Lt −0.052 0.590
2. BMI (sq.m) IPL I-III Rt 0.095 0.321
Lt −0.008 0.931
IPL III-V Rt 0.095 0.321
Lt −0.008 0.931
IPL I-V Rt 0.274 0.003
Lt 0.210 0.027
3. HbA1c (%) IPL I-III Rt 0.274 0.003
Lt 0.210 0.027
IPL III-V Rt 0.130 0.176
Lt 0.121 0.208
IPL I-V Rt 0.296 0.001
Lt 0.296 0.001
IPLs in milli seconds, Rt – right, Lt – left.
Table 3. 
Correlation of independent variables and IPLs in all subjects.
S.No Independent 
variable
Dependent variable Ear r-value p-value
1 Age (years) IPL I-III Rt −0.571 0.084
Lt −0.523 0.121
IPL III-V Rt −0.737 0.014
Lt −0.499 0.142
IPL I-V Rt −0.705 0.022
Lt −0.733 0.015
2 BMI (sq.m) IPL I-III Rt 0.742 0.013
Lt 0.215 0.550
IPL III-V Rt 0.523 0.121
Lt 0.471 0.170
IPL I-V Rt 0.549 0.100
Lt 0.496 0.145
3 HbA1c (%) IPL I-III Rt −0.431 0.335
Lt −0.355 0.314
IPL III-V Rt −0.436 0.208
Lt −0.282 0.430
IPL I-V Rt −0.392 0.263
Lt −0.354 0.315
IPLs in milli seconds, Rt – right, Lt – left.
Table 2. 
Correlation of independent variables and IPLs in normal subjects.
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Figure 7. 
Correlation of IPL I-III and age in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
Figure 8. 
Correlation of IPL III-V and age in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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Figure 9. 
Correlation of IPL I-V and age in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. The 
‘r’ and P values are correlating WoHI and WHI right and left ear.
Figure 10. 
Correlation of IPL I-III and BMI in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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Figure 11. 
Correlation of IPL III-V and BMI in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
Figure 12. 
Correlation of IPL I-V and BMI in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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Figure 13. 
Correlation of IPL I-III and HbA1c in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
Figure 14. 
Correlation of IPL III-V and HbA1c in type 2 diabetes, without (WoHI) and with (WHI) hearing 
impairment. The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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the right ear of WoHI (P = 0.758) and WHI (P = 0.128) group and left ear of 
WHI (P = 0.377) group showed negative correlation with BMI. In IPL III-V, 
the right ear (P = 0.284) of WoHI group and left ear (P = 0.543) of WHI group 
showed negative correlation with BMI. In IPL I-V, the right ear (P = 0.179) of 
WoHI group and left ear (P = 0.443) of WHI group shows negative correlation 
with BMI.
The correlation of IPL I-III, III-V and I-V values and HbA1c for both the ears in 
WoHI and WHI groups were given in Figures 13–15. In both the groups IPL I-III, 
III-V and I-V values were not statistically correlated with HbA1c. In IPL I-III, left 
ear of WoHI group shows negative correlation with HbA1c (P = 0.277). In IPL III-V, 
right ear of WoHI group shows negative correlation with HbA1c (P = 0.755). In IPL 
I-V, WoHI group right (P = 0.392) and left (P = 0.910) ears shows negative correla-
tion with HbA1c.
5. Discussion
The BAER is a simple, non-invasive procedure to detect early impairment of 
auditory nerve and auditory pathway even in the absence of specific symptoms in the 
diabetic patients. The present study strongly recommended that BAER is carried out 
in all diabetic patients to detect the involvement of central neuronal pathway and peri-
odic evaluation in of diabetes for early intervention regarding metabolic regulations.
Figure 15. 
Correlation of IPL I-V and HbA1c in type 2 diabetes, without (WoHI) and with (WHI) hearing impairment. 
The ‘r’ and P values are correlating WoHI and WHI right and left ear.
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The inter peak latencies of BAER tells about the time required for processing 
from one site to the next site in the auditory pathway [11]. In the present study, 
WHI group IPL I-III, III-V and I-V of both ears and left ear IPL III-V increased when 
compared to the normal subjects and WoHI group. These findings are in line with 
the previous research who found significant changes in the IPLs of the diabetics 
when compared to the controls [7, 12–16].
The prolongation of IPLs I-III, III-V and I-V are indicated central conduction 
delay at the level of brainstem and midbrain in the auditory pathway of diabetics. 
These prolongations are due to neuropathy at brainstem and midbrain level. These 
findings are supported by previous research [16]. In the present study, WHI group 
left ear IPL I-V values are decreased minimally when compared to WoHI group left 
ear IPL I-V values. Metformin (N, N-dimethylbiguanidine) is a widely used oral 
hypoglycaemic agent in T2DM; it has a potential anti-ototoxic activity. It prevents 
oxidative stress induced cell death and inhibition of lipid peroxidation and also 
scavenges hydroxyl radicals by modulating NADPH oxidase and inhibits apoptotic 
cascades by increasing the expression of the anti-apoptotic protein Bcl-2 [17]. This 
is the probable mechanism responsible for the reduced IPL values in the WHI group 
who are on metformin treatment.
The IPLs I-III, III-V and I-V of both the ears in WoHI and WHI groups were not 
correlated with the age, BMI and HbA1c values. The present study is contradicting 
with the previous research [18]. The HbA1c values are not correlated with the IPLs 
of both ears in WoHI and WHI groups. This finding is in line with the previous 
research [19–21] and contradicting with other studies [7]. In diabetes, hyperglycae-
mia results many pathological changes in nervous tissue by apoptosis, nerve energy 
deficits, intracellular calcium excitotoxicity, glycosylated products, oxidative stress, 
hypoxia and ischemia [22]. In the peripheral nervous system the myelin sheath and 
other nerve components are affected by hyperglycaemia [23].
In the present study, BMI and HbA1c values were correlated with the IPL I-III 
and I-V of both the ears in all subjects; it indicated that, with increase in BMI 
and HbA1c values the IPL values are increased in diabetic subjects. This finding 
is in line with the previous research where inter peak latencies were prolonged in 
uncontrolled T2DM subjects [24]. The inter peak latencies were prolonged in T2DM 
patients with duration of diabetes more than 7 years [24].
In diabetic neuropathy, hyperglycaemia accumulates diacylglycerol and activates 
PKC; this PKC causes transcription changes in the contractile proteins fibronectin, 
type IV collagen, and extracellular matrix (ECM) proteins in neurons and endothe-
lial cells [25]. Due to this the affected neurons had degenerated axons, so that the 
amplitude of the neural conduction alters and the conduction velocity decreases in 
that affected nerves [26]. This is one of the reason to increase the inter peak laten-
cies in the hearing impaired persons with T2DM in the present study. The present 
study is in line with the previous research with prolonged inter peak latencies in 
the T2DM patients [27, 28]. Another mechanism involved in the reduced neural 
transmission in T2DM with hyperglycaemia is oxidative stress with reactive oxygen 
species, these causes dendritic damage in the affected neurons with microglial 
activation [28–31] with prolongation of inter peak latencies.
Diabetes associated disruption between insulin activity and glucose metabolism 
results in decreased cerebral blood flow and oxidative glucose metabolism with 
impairment of neurotransmission. Diabetes has been widely associated with slowly 
progressive end-organ damage in brain resulting in diabetic neuropathy and/or mild 
to moderately impair cognitive function, both in type 1 and type 2 diabetic patients. 
The molecular mechanisms involved in the CNS damage in diabetes are hypoth-
esized that AGEs formation, aldose reductase activity, oxidative stress, activation of 
protein kinase C and increased hexosamine pathway flux [32].
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Chronic hyperglycaemia elicits pathophysiological changes to the nervous 
system as a result of oxidative stress, nerve energy deficits, decreased Na/K/ATPase 
activity and decreased neurotrophism. The damage to myelin sheaths and other 
nerve components as a result of hyperglycaemia occurs prominently in the periph-
eral nervous system but also in the spinal cord, cranial, optic and vestibular nerves. 
In the peripheral nervous system major myelin proteins are glycosylated, perhaps 
making them more prone to the effects of AGE, while in the CNS major myelin 
proteins are not glycosylated. The glial margin demarcates the boundary of the 
peripheral and central auditory systems, and is located about halfway between the 
cochlea and the cochlear nucleus [33]. These findings may explain why the periph-
eral auditory function was more affected than the central auditory nervous system 
in the present study. In diabetics, the IPLs I-III and I-V were positively correlated 
with autonomic score and large sensory nerve dysfunction. The abnormalities of 
waves III and V indicated an impairment of the auditory brainstem function in 
diabetic neuropathy [34].
The T2DM affects the cognitive function. The higher concentrations of neuron 
specific enolase (NSE) protein in long standing T2DM result permanent brain 
damage and was correlated with poor cognitive performance. Its concentration 
increased by oxidative stress and neuronal apoptosis and these changes reversed 
with insulin treatment [35]. In T2DM, the P300 event related potentials (ERPs) 
revealed early cognitive dysfunction which was not detected by neuro-psychomet-
ric test mini mental state examination (MMSE) and it was more prominent when 
the disease duration more than 5 years. When the T2DM is associated with hyper-
tension, further increases the risk of cognitive impairment [36].
6. Conclusion
The present study explains about the inter peak latency changes of the brain-
stem auditory evoked potentials in T2DM. BAER was performed in normal sub-
jects, WoHI and WHI groups for both the ears. Compared the inter peak latencies 
I-III, III-V and I-V between normal subjects, WoHI and WHI groups. Correlated 
age, BMI and HbA1c values with inter peak latencies in normal subjects, WoHI 
and WHI groups for both the ears. Age, BMI and HbA1c are not correlated with 
increase in inter peak latencies for both the ears in WHI group. The BMI and HbA1c 
values were correlated with IPL I-V of both the ears in all subjects.
We focused on functional changes but not anatomical changes. Because, 
functional changes can happen without any visible anatomical changes. For the 
assessment of structural changes we need CT or MRI brain which are highly 
cost, time consuming, radio-hazard and the subject may face inconvenience. 
However BAER can overcome all these circumstances. India is a country with 
large number of population with diabetes, insists the necessity to focus on long 
term hearing loss among them. BAER test is the very feasible method to perform 
at regular intervals for record. It could help to take necessary action to prevent 
hearing loss.
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